ZA200006262B - Pharmaceutical composition for the treatment of diabetes. - Google Patents
Pharmaceutical composition for the treatment of diabetes. Download PDFInfo
- Publication number
- ZA200006262B ZA200006262B ZA200006262A ZA200006262A ZA200006262B ZA 200006262 B ZA200006262 B ZA 200006262B ZA 200006262 A ZA200006262 A ZA 200006262A ZA 200006262 A ZA200006262 A ZA 200006262A ZA 200006262 B ZA200006262 B ZA 200006262B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical composition
- anorectic
- composition according
- insulin sensitizer
- combination
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 34
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 19
- -1 5-methyl-2-phenyloxazol-4- yl Chemical group 0.000 claims description 50
- 230000001539 anorectic effect Effects 0.000 claims description 31
- 206010061428 decreased appetite Diseases 0.000 claims description 31
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 30
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical group Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 229960002827 pioglitazone hydrochloride Drugs 0.000 claims description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 6
- 229960001641 troglitazone Drugs 0.000 claims description 6
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 6
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 6
- 208000002249 Diabetes Complications Diseases 0.000 claims description 5
- 206010012655 Diabetic complications Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229960000299 mazindol Drugs 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 229960004586 rosiglitazone Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000011593 sulfur Chemical group 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 125000002723 alicyclic group Chemical group 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KMXXSJLYVJEBHI-UHFFFAOYSA-N 3-guanidinopropanoic acid Chemical compound NC(=[NH2+])NCCC([O-])=O KMXXSJLYVJEBHI-UHFFFAOYSA-N 0.000 description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001485 cycloalkadienyl group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 125000004586 dihydrobenzopyranyl group Chemical group O1C(CCC2=C1C=CC=C2)* 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001326 naphthylalkyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18370098 | 1998-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200006262B true ZA200006262B (en) | 2001-11-02 |
Family
ID=16140426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200006262A ZA200006262B (en) | 1998-06-30 | 2000-11-02 | Pharmaceutical composition for the treatment of diabetes. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6329403B1 (fr) |
| EP (1) | EP1093370B1 (fr) |
| KR (1) | KR20010043455A (fr) |
| CN (1) | CN1305376A (fr) |
| AR (1) | AR019727A1 (fr) |
| AT (1) | ATE318138T1 (fr) |
| AU (1) | AU754740B2 (fr) |
| BR (1) | BR9911656A (fr) |
| CA (1) | CA2329004C (fr) |
| DE (1) | DE69929996T2 (fr) |
| DK (1) | DK1093370T3 (fr) |
| ES (1) | ES2255316T3 (fr) |
| ID (1) | ID27415A (fr) |
| NO (1) | NO20006630L (fr) |
| WO (1) | WO2000000195A1 (fr) |
| ZA (1) | ZA200006262B (fr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607751B1 (en) * | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| WO2000078333A2 (fr) | 1999-06-21 | 2000-12-28 | Eli Lilly And Company | Utilisation combinee de thiazolidinediones et de peptide-1 de type glucagone et d'agonistes de ces derniers pour traiter l'instabilite metabolique associee aux diabetes non insulino-dependants. |
| AT409081B (de) * | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| EP1295609A4 (fr) * | 2000-02-24 | 2004-11-03 | Takeda Chemical Industries Ltd | Medicaments contenant des ingredients actifs combines |
| GB0021978D0 (en) * | 2000-09-07 | 2000-10-25 | Smithkline Beecham Plc | Novel pharmaceutical |
| JP2004331500A (ja) * | 2001-02-16 | 2004-11-25 | Dainippon Pharmaceut Co Ltd | 血中濃度制御製剤 |
| US20040143015A1 (en) * | 2001-03-12 | 2004-07-22 | Villhauer Edwin Bernard | Combination of organic compounds |
| KR200249057Y1 (ko) * | 2001-03-22 | 2001-10-19 | 김진환 | 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치 |
| WO2002081751A2 (fr) * | 2001-04-03 | 2002-10-17 | The Regents Of The University Of California | Procede permettant d'augmenter la production de leptine endogene |
| US20070203225A1 (en) * | 2001-04-03 | 2007-08-30 | Havel Peter J | Method of increasing endogenous adiponectin production and leptin production |
| JP2002360666A (ja) * | 2001-06-11 | 2002-12-17 | Takeda Chem Ind Ltd | コバルト合金を用いた打錠用杵臼 |
| JP2005518408A (ja) | 2001-12-29 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | 異常脂肪血症を治療するための、ｇｌｐ−１化合物と他の薬物との組み合わせ使用 |
| US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| WO2003063889A1 (fr) * | 2002-01-31 | 2003-08-07 | Joslin Diabetes Center, Inc. | Procedes de modulation de la fonction des lymphocytes b |
| US8911781B2 (en) | 2002-06-17 | 2014-12-16 | Inventia Healthcare Private Limited | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides |
| EP1388352A1 (fr) * | 2002-08-08 | 2004-02-11 | Laboratoires Fournier S.A. | Utilisation d'un agoniste de PPAR-alpha pour traiter l'obesité associée au traitement avec un agonist de PPAR-gamma dans des patients |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US9060941B2 (en) * | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7959946B2 (en) * | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| WO2004078716A1 (fr) * | 2003-03-03 | 2004-09-16 | Merck & Co. Inc. | Derives de piperazine acyles utilises comme agonistes des recepteurs de la melanocortine 4 |
| US20050187266A1 (en) * | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
| US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| US7008957B2 (en) * | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
| US7264813B2 (en) | 2003-09-24 | 2007-09-04 | Nikken Sohonsha Corporation | Therapeutic uses of Dunaliella powder |
| EP2140865A1 (fr) * | 2003-11-14 | 2010-01-06 | Vertex Pharmaceuticals Incorporated | Thiazoles et oxazoles utiles en tant que modulateurs de transporteurs de cassette à liaison ATP |
| EP1727559A1 (fr) * | 2004-01-26 | 2006-12-06 | Eli Lilly And Company | Utilisation de fgf-21 et d'une thiazolidinedione pour traiter le diabete de type 2 |
| AR047541A1 (es) * | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| WO2005092040A2 (fr) * | 2004-03-22 | 2005-10-06 | The Regents Of The University Of California | Formulation pour ameliorer la production de leptine et d'adiponectine endogene |
| US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
| US10624858B2 (en) * | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| GB2435770B (en) * | 2004-12-03 | 2010-05-05 | Vetco Gray Scandinavia As | Hybrid control system and method |
| KR100697983B1 (ko) * | 2005-07-08 | 2007-03-23 | 대봉엘에스 주식회사 | 신규 중간체 및 이를 이용한 피오글리타존의 제조방법 |
| KR100697982B1 (ko) * | 2005-07-08 | 2007-03-23 | 대봉엘에스 주식회사 | 로시글리타존의 제조방법 |
| US20070129444A1 (en) * | 2005-12-06 | 2007-06-07 | Mallinckrodt Inc. | Novel weight reduction composition and uses thereof |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| CN101453993A (zh) | 2006-04-03 | 2009-06-10 | 伊萨·奥迪迪 | 含有机溶胶涂层的受控释放递送物件 |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| EP2016076A2 (fr) * | 2007-01-22 | 2009-01-21 | Teva Pharmaceutical Industries Ltd. | Formes polymorphes d'hydrobromure de rosiglitazone et leurs procédés de préparation |
| WO2008121496A1 (fr) * | 2007-03-30 | 2008-10-09 | Tioga Pharmaceuticals Inc. | Agonistes du récepteur opiacé kappa pour le traitement du syndrome du côlon irritable avec alternance ou à diarrhée prédominante |
| US20090318520A1 (en) | 2008-06-20 | 2009-12-24 | Afecta Pharmaceuticals Drive | Use of isoindoles for the treatment of neurobehavioral disorders |
| EP2635296B1 (fr) * | 2010-11-03 | 2014-12-24 | Arecor Limited | Nouvelle composition contenant de glucagon |
| DK2916852T3 (en) * | 2012-11-06 | 2021-05-10 | Sigrid Therapeutics Ab | A porous silica material for use as a pharmaceutical or dietary active ingredient |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| WO2018160178A1 (fr) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Sels pharmaceutiquement acceptables d'acide bêta-guanidinopropionique ayant des propriétés améliorées et utilisations de ceux-ci |
| AU2020402994A1 (en) | 2019-12-11 | 2022-06-23 | Inspirna, Inc. | Methods of treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2030174C (fr) * | 1990-01-10 | 1996-12-24 | Anthony H. Cincotta | Procede pour la reduction a long terme des reserves lipidiques, de l'insulinoresistance, de l'hyperinsulinemie et de l'hypoglycemie chez les vertebres |
| GB9111426D0 (en) | 1991-05-28 | 1991-07-17 | Ici Plc | Chemical compounds |
| DE69219136T2 (de) * | 1991-08-26 | 1997-08-28 | Pharmacia & Upjohn Co., Kalamazoo, Mich. | Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| CA2244831A1 (fr) * | 1996-02-02 | 1997-08-07 | John T. Olson | Methode de traitement du diabete et d'etats pathologiques associes |
| GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
-
1999
- 1999-06-29 CA CA002329004A patent/CA2329004C/fr not_active Expired - Fee Related
- 1999-06-29 WO PCT/JP1999/003496 patent/WO2000000195A1/fr active IP Right Grant
- 1999-06-29 ES ES99957622T patent/ES2255316T3/es not_active Expired - Lifetime
- 1999-06-29 BR BR9911656-1A patent/BR9911656A/pt not_active IP Right Cessation
- 1999-06-29 AT AT99957622T patent/ATE318138T1/de active
- 1999-06-29 DE DE69929996T patent/DE69929996T2/de not_active Expired - Lifetime
- 1999-06-29 EP EP99957622A patent/EP1093370B1/fr not_active Expired - Lifetime
- 1999-06-29 DK DK99957622T patent/DK1093370T3/da active
- 1999-06-29 AR ARP990103124A patent/AR019727A1/es unknown
- 1999-06-29 CN CN99807133A patent/CN1305376A/zh active Pending
- 1999-06-29 US US09/380,059 patent/US6329403B1/en not_active Expired - Fee Related
- 1999-06-29 ID IDW20002745A patent/ID27415A/id unknown
- 1999-06-29 AU AU42914/99A patent/AU754740B2/en not_active Ceased
- 1999-06-29 KR KR1020007012502A patent/KR20010043455A/ko not_active Application Discontinuation
-
2000
- 2000-11-02 ZA ZA200006262A patent/ZA200006262B/en unknown
- 2000-12-22 NO NO20006630A patent/NO20006630L/no not_active Application Discontinuation
-
2001
- 2001-12-29 US US10/036,208 patent/US20020086885A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6329403B1 (en) | 2001-12-11 |
| KR20010043455A (ko) | 2001-05-25 |
| ES2255316T3 (es) | 2006-06-16 |
| WO2000000195A1 (fr) | 2000-01-06 |
| ID27415A (id) | 2001-04-05 |
| DE69929996T2 (de) | 2006-11-16 |
| EP1093370B1 (fr) | 2006-02-22 |
| CA2329004A1 (fr) | 2000-01-06 |
| US20020086885A1 (en) | 2002-07-04 |
| DE69929996D1 (de) | 2006-04-27 |
| CA2329004C (fr) | 2009-04-14 |
| AR019727A1 (es) | 2002-03-13 |
| NO20006630D0 (no) | 2000-12-22 |
| EP1093370A1 (fr) | 2001-04-25 |
| DK1093370T3 (da) | 2006-05-22 |
| AU4291499A (en) | 2000-01-17 |
| CN1305376A (zh) | 2001-07-25 |
| AU754740B2 (en) | 2002-11-21 |
| NO20006630L (no) | 2001-02-26 |
| ATE318138T1 (de) | 2006-03-15 |
| BR9911656A (pt) | 2001-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200006262B (en) | Pharmaceutical composition for the treatment of diabetes. | |
| JP3973280B2 (ja) | 医薬 | |
| TWI249401B (en) | Agent for improving ketosis | |
| JP4976281B2 (ja) | 代謝を調節するための材料および方法 | |
| WO1999009965A2 (fr) | Agent antiinflammatoire | |
| JP2000080047A (ja) | 医 薬 | |
| ZA200505762B (en) | Arlycycloalkyl derivatives with branched side chains as ppar receptor modulators, method for their producion and their use as medicament | |
| ZA200505766B (en) | Cycloalkyl-substituted alkanoic acid derivatives methods for the production thereof and use thereof as a medicament | |
| MXPA00010582A (en) | Pharmaceutical composition for the treatment of diabetes | |
| EP1757287A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies liées au métabolisme des lipides | |
| HRP20000256A2 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| HRP20000255A2 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| AU4086700A (en) | Pharmaceutical composition |